Virtual patient 'surrogates' can personalize cancer treatments
Scientists have developed mathematical models that act as patient 'surrogates' for evaluating potential prostate cancer treatments.
Feb 15, 2022
0
7
Scientists have developed mathematical models that act as patient 'surrogates' for evaluating potential prostate cancer treatments.
Feb 15, 2022
0
7
High doses of a widely-used drug used in the hormonal treatment of conditions such as excessive hair growth, early puberty, prostate cancer, are linked to an increased risk of meningioma—the most common type of benign ...
Feb 4, 2022
1
236
A new risk calculator developed by a University of Alberta researcher and collaborators in the United States could reduce the number of unnecessary and invasive biopsies for prostate cancer.
Feb 4, 2022
0
7
New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk classification system that groups prostate cancer patients based on their risk of recurrence. Prostate-specific membrane antigen ...
Jan 21, 2022
0
17
Advanced forms of hormone therapy are very effective at keeping prostate cancer in check, but they also can double a man's risk of falling into depression, researchers have found.
Jan 18, 2022
0
32
A molecular feature in prostate cancer, called endogenous retroviral (ERV) RNA, has been found to have prognostic value and also distinguish differences between men of African and European or Middle Eastern ancestry, according ...
Jan 13, 2022
0
26
More than one in 10 patients with localized prostate cancer experience treatment-related regret—a sense of disappointment with their treatment compared to other treatment options—according to a recent study published ...
Dec 13, 2021
0
0
A multi-institutional team of investigators led by bioengineer Ankur Singh has developed research tools that shed new light on a virtually untreatable form of prostate cancer, opening a pathway that may lead to novel therapeutics ...
Nov 24, 2021
0
16
The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies ...
Nov 2, 2021
0
2
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021
0
29